Latest Blogs

Mar 11, 2019
For many of us not a day has gone by without some reminder of Arti, but last week brought it all back into sharp focus as I was asked to talk about the role we at ASCO played in her career during a symposium in her honor.
Mar 11, 2019
Wherever we practice, none of us need to look very far to find people who, through no fault of their own, are living right on the knife’s edge of disaster.
Mar 01, 2019
The Beirut Breast Cancer Conference is a modern multidisciplinary specialty oncology regional meeting that provides excellent onsite dissemination of knowledge and research.
Feb 27, 2019
Dr. Ashley Sumrall fulfilled a dream of performing in the famous Carnegie Hall, and discovered that the practice, teamwork, and commitment required onstage paralleled her work in oncology.
Subscribe to this column

L. Michael Glode, MD, FACP, FASCO

L. Michael Glodé, MD, FACP, FASCO, is a Professor Emeritus at the University of Colorado Cancer Center. He previously served as Chair of ASCO's Integrated Media and Technology and Cancer Education Committees. He is the author of prost8blog, a blog to help patients and their families understand various aspects of prostate cancer.

Aug 31, 2018
Some reflections on John McCain, mortality, Hamilton, and the story you leave behind. 
Dec 21, 2016
I cannot count the number of times I have thought to myself, “If it were not for the PSA, you would no doubt be out there playing golf, skiing, biking, taking a grandchild to the park, or just enjoying life.” Living from one PSA to the next is a bad way to mark the passing of time.
Aug 08, 2016
For prostate cancer, there are both challenges and some early positive results from immunotherapy trials that remain intriguing. One of the key challenges is identifying those patients who will benefit from the treatment.
Jun 05, 2016
Much of the news this week in prostate cancer will be generated by the ASCO Annual Meeting in Chicago. There are likely to be considerable news releases regarding precision medicine, and especially AR-V7, so I thought I would explain this a bit.
Feb 16, 2016
In what is the first (and hopefully one of many) example of using modern genomic methods to match treatments to the molecular defects in prostate cancer, the U.S. FDA has just granted “breakthrough designation” to olaparib.
Jan 06, 2016
One of the most frequent questions I hear in my clinic is, “Are we making any progress?” or, “Is there anything new out there?” The answer is always yes, or more properly, YES!

Pages